Health technology assessment reports for oncology medications in Canada from 2018 to 2025: methodological critiques on manufacturers’ submissions and a comparison between manufacturers and Canada’s Drug Agency (CDA) analyses
Using MAIC or naïve ITC, submitting a dossier that includes limited clinical evidence, and surrogate outcomes are associated with a negative recommendation.
Authors
- Fatemeh Mirzayeh Fashami (ORCID: https://orcid.org/0000-0003-0189-9065)
- Mobina Dokhaei (ORCID: https://orcid.org/0000-0002-4474-8964)
- Kimia Hariri (ORCID: https://orcid.org/0000-0002-1071-5515)
- Naeemeh Dini
- Mitchell Levine
- Sepideh Mardani Jadid
- Masoud Tajadod
- Dorsa Azizi Khezri
Institutions
- Brighton Hospital (US)
- BrightOutcome (United States) (US)
- St. Joseph’s Healthcare Hamilton (CA)
- McMaster University (CA)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1080/14737167.2026.2632265
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00